Purchase this article with an account.
E. H. Sohn, SITAS International Study Group; Long-Term Evaluation of Triamcinolone Acetonide Subconjunctival Delivery for Anterior Scleritis (SITAS). Invest. Ophthalmol. Vis. Sci. 2010;51(13):5269.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We sought to characterize the long-term efficacy and complications of subconjunctival steroid injection (SCI) for non-necrotizing, noninfectious anterior scleritis.
97 eyes of 80 patients with non-necrotizing and non-infectious scleritis who underwent subconjunctival injections of triamcinolone acetonide (4-40 mg depending on type of scleritis) were selected from 10 participating clinical centers in the US, Israel, Singapore, and Australia.
Average follow-up was 28 months (range 1-100 months). 87 eyes (90%) experienced resolution of signs and symptoms after one injection. 24 months after injection, 65% of eyes remained recurrence free while at 48 months, 45% were recurrence free. 12 eyes had ocular hypertension not requiring IOP-lowering therapy. 2 patients were treated with topical IOP-lowering agents alone while 3 needed surgical intervention for glaucoma. None developed scleral thinning or necrosis.
SCI can effectively treat anterior scleritis with side effects limited to elevated intraocular pressure in few patients. Intraocular pressure should be closely monitored after SCI.
This PDF is available to Subscribers Only